The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.175
Bid: 9.25
Ask: 9.85
Change: 0.00 (0.00%)
Spread: 0.60 (6.486%)
Open: 9.175
High: 0.00
Low: 0.00
Prev. Close: 9.175
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Nov 2015 16:48

RNS Number : 4466H
e-Therapeutics plc
30 November 2015
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

e-Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

X

3. Full name of person(s) subject to thenotification obligation: iii

Henderson Group plc

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

26 November 2015

6. Date on which issuer notified:

30 November 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

Above 5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

24,482,842

24,482,842

 

 

26,168,691

 

 

 

 

9.89%

GB00B2823H99

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

26,168,691

9.89%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

See Annex 1 below.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

 

Revised Transparency Directive notification.

 

This disclosure has been calculated based on total voting rights of 264,455,551.

 

14. Contact name:

HGIThresholdDisclosures@henderson.com

15. Contact telephone number:

020 7818 5738 / 4184

 

Annex 1: Information in relation to the person subject to the notification obligation (please tick the applicable box):

 

[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii

 

[X] Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, AlphaGen Capital Limited

Below 5%

0

Below 5%

Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, Henderson Global Investors Limited

9.48%

0

9.48%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAKFEDLLSFFF
Date   Source Headline
20th Jun 20144:22 pmRNSHolding(s) in Company
20th Jun 20141:41 pmRNSHolding(s) in Company
18th Jun 20146:14 pmRNSAdditional Listing
30th May 20147:00 amRNSAnnual Financial Report and Notice of AGM
22nd May 20144:15 pmRNSIssue of Equity
12th May 20147:00 amRNSFull year results
8th May 20147:00 amBUSe-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial
2nd May 20144:46 pmRNSHolding(s) in Company
2nd May 20144:42 pmRNSHolding(s) in Company
2nd May 20144:29 pmRNSHolding(s) in Company
25th Apr 20147:00 amRNSNotice of Results
7th Apr 20141:07 pmRNSDirectorate Change
7th Apr 201411:46 amRNSDirectorate Change
31st Mar 20146:56 amBUSe-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours
26th Mar 20147:00 amBUSe-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial
10th Feb 20147:02 amBUSe-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers
24th Jan 20147:00 amBUSTemporary halt of recruitment into ETS2101 cancer trials because of drug supply issue - Patients already being treated will continue to be dosed
9th Jan 20142:34 pmRNSAdditional Listing
7th Jan 20147:00 amBUSStatement re e-Therapeutics provides update on ETS2101 phase I trial in brain cancer
31st Oct 20137:00 amBUSResearch Update
16th Oct 20137:00 amBUSHalf-yearly Report
30th Sep 20134:45 pmRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSNotice of Interim Results
6th Aug 201312:43 pmRNSAdditional Listing
1st Aug 20134:53 pmRNSDirector/PDMR Shareholding
30th Jul 20133:30 pmRNSDirector/PDMR Shareholding
25th Jul 201311:09 amRNSResult of AGM
24th Jul 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20134:41 pmRNSDirector/PDMR Shareholding
1st Jul 20139:00 amRNSNotice of AGM and Annual Report
21st Jun 20137:00 amRNSProactive Investors One2One Forum 26th Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
14th May 20137:00 amBUSPreliminary results for the year ended 31 January 2013
18th Apr 20137:00 amRNSNotice of Results
4th Apr 20135:18 pmRNSDirector/PDMR Shareholding
25th Mar 201310:44 amRNSHolding(s) in Company
18th Mar 20135:19 pmRNSIssue of Equity
13th Mar 20136:19 pmRNSHolding(s) in Company
6th Mar 201310:01 amRNSHolding(s) in Company
5th Mar 20135:44 pmRNSHolding(s) in Company
4th Mar 20133:31 pmRNSHolding(s) in Company
4th Mar 20133:23 pmRNSDirector/PDMR Shareholding
4th Mar 20132:56 pmRNSHolding(s) in Company
1st Mar 20137:00 amRNSCompletion of the Placings
28th Feb 201312:01 pmRNSCompletion of First Placing / Issue of Equity
27th Feb 201310:01 amRNSResult of General Meeting / Issue of Equity
22nd Feb 20132:51 pmRNSDirector/PDMR Shareholding
19th Feb 20139:45 amRNSDirector/PDMR Shareholding
15th Feb 20132:27 pmRNSDirector/PDMR Shareholding
14th Feb 20137:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.